Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832771 | 0.89 | OPRM1 (0.49) | ACEBDKRB2OPRM1OPRD1NTSR2 | |
| SCHEMBL29695547 | 0.87 | OPRM1 (0.49) | ACEBDKRB2OPRM1OPRD1NTSR2 | |
| SCHEMBL30542977 | 0.84 | OPRM1 (0.46) | BDKRB2OPRM1OPRD1NTSR2NTSR1 | |
| SCHEMBL31000886 | 0.83 | NTSR1 (0.55) | BDKRB2OPRM1OPRD1NTSR2NTSR1 | |
| SCHEMBL30542990 | 0.83 | OPRM1 (0.49) | ACEBDKRB2OPRM1OPRD1NTSR2 | |
| SCHEMBL8937037 | 0.83 | OPRD1 (0.66) | BDKRB2OPRM1OPRD1 | |
| SCHEMBL29541526 | 0.82 | ITGB3 (0.40) | ACEBDKRB2OPRM1OPRD1ITGB3 | |
| SCHEMBL30695667 | 0.82 | BDKRB2 (0.47) | ACEBDKRB2OPRM1OPRD1NTSR2 | |
| SCHEMBL29363178 | 0.82 | ACE (0.59) | ACE | |
| SCHEMBL29935575 | 0.82 | ITGB3 (0.49) | ACEBDKRB2NTSR2NTSR1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304706-A1 | ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY | ASTELLAS PHARMA INC. (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4606384-A1 | USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT | Astellas Pharma, Inc. (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-12304951-B2 | Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody | ASTELLAS PHARMA INC. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20250154272-A1 | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | ASTELLAS PHARMA INC. (JP) | 2025-05-15 | — | — | US | disclosed |
| CN-119997975-A | Use of anti-CLDN 4-anti-CD 137 bispecific antibodies in cancer treatment by combination with PD-1 signaling inhibitors | 安斯泰来制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025070337-A1 | ANTI-MERTK AGONIST ANTIBODY, ANTI-MERTK BISPECIFIC ANTIBODY, AND USE THEREOF | アステラス製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4524248-A1 | ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY | Astellas Pharma, Inc. (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-12227586-B2 | Anti-CLDN4/anti-CD137 bispecific antibody | ASTELLAS PHARMA INC. (JP) | 2025-02-18 | — | — | US | disclosed |
| CN-119173633-A | Anti-TAA-anti-CD 3 multispecific antibodies | 安斯泰来制药株式会社 | 2024-12-20 | — | — | CN | disclosed |
| US-20240209108-A1 | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | ASTELLAS PHARMA INC. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11897954-B2 | Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody | ASTELLAS PHARMA INC. (JP) | 2024-02-13 | — | — | US | disclosed |
| CN-117222672-A | anti-CLDN 4-anti-CD 137 bispecific antibodies | 安斯泰来制药株式会社 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023219120-A1 | ANTI-CD37/ANTI-CD3 BISPECIFIC ANTIBODY | アステラス製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023219121-A1 | ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY | アステラス製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| US-20230348587-A1 | ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | ASTELLAS PHARMA INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023199927-A1 | USE OF ANTI-TSPAN8-ANTI-CD3 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT | アステラス製薬株式会社 | 2023-10-19 | — | — | WO | disclosed |
| EP-4245855-A1 | ANTI-TSPAN8-ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | Astellas Pharma Inc. (JP) | 2023-09-20 | — | — | EP | disclosed |
| CN-116635071-A | anti-TSPAN 8-anti-CD 3 bispecific antibodies and anti-TSPAN 8 antibodies | 安斯泰来制药株式会社 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022224997-A1 | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | アステラス製薬株式会社 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022102768-A1 | ANTI-TSPAN8-ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | アステラス製薬株式会社 | 2022-05-19 | — | — | WO | disclosed |